Navigation Links
Central European Society for Anticancer Drug Research Announces Start of Enrollment in First Randomized Trial of Pharmacokinetic-Guided Dose Adjustment of Paclitaxel in Non-Small Cell Lung Cancer
Date:4/26/2011

VIENNA and BETHLEHEM, Pa., April 26, 2011 /PRNewswire/ -- In collaboration with Saladax Biomedical, Inc., the Central European Society for Anticancer Drug Research (CESAR) announced today that enrollment has begun in the CEPAC-TDM trial of paclitaxel therapeutic drug management (TDM) with subsequent pharmacokinetic-guided dose adjustment in patients being treated for advanced non-small cell lung cancer (NSCLC).  The study will determine if optimizing dosing of paclitaxel will reduce grade 4 neutropenia, without affecting progression-free survival and overall survival.  Saladax is developing a nanoparticle-based automated immunoassay to provide rapid, simple and cost-effective measurement of paclitaxel levels to allow timely personalized dose adjustment.

This multicenter randomized trial is planned to enroll 280 patients.  In the first phase of the study, eight study centers will participate in Germany and Switzerland, with the first three patients already enrolled in Lowenstein, Germany.  The study is sponsored by CESAR and supported by Saladax Biomedical.

The CEPAC-TDM study is the first large scale, randomized trial to evaluate the clinical utility of paclitaxel drug dose management and is the largest randomized trial of its type.  A dosing algorithm has been derived that uses 24-hour paclitaxel plasma concentration and clinical parameters, based on a large population model of paclitaxel. In addition to the clinical results, extensive data on health economic outcomes will be generated through the trial.

Markus Joerger, MD PhD, explains: "The CEPAC-TDM clinical trial has the potential to markedly improve patient quality of life through a reduction of febrile neutropenia and hospitalization, and debilitating neuropathy, as it tailors paclitaxel to the individual patient's drug metabolism."

Study details

The CEPAC-TDM study is a phase III open-label, randomized, parallel-group clinical trial compar
'/>"/>

SOURCE Saladax Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Symmetry Medical Centralizes Businesses Under CEO
2. Central Texas Hospital Selects eCareSoft EHR Technology
3. FDA Approves Gadavist for Central Nervous System Scans
4. U.S. FDA Approves Bayers Gadavist™ (Gadobutrol) Injection for MRI of the Central Nervous System
5. Mithridion, Inc. Announces New Funding and Outlines Strategy for Central Nervous System Drug Development
6. Reportlinker Adds The Outlook for Pharmaceuticals in Central Asia
7. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
8. Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME)
9. Cipher Pharmaceuticals Using MedAvante Centralized Ratings in Phase 3 Study
10. Rexahn to Use MedAvante Centralized Ratings in MDD Phase 2b Study
11. Wound Management Technologies Adds Panama to Growing List of Distribution Points in Central America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... RALEIGH, N.C. and ,S-HERTOGENBOSCH, the ... Europe ( http://www.healthlinkeurope.com ) has expanded its North American ... 100% medical facility, providing warehousing, fulfillment and order to ... North America , utilizing our global ERP platform. ... since 1994 serving our customers in Europe ...
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire-iReach/ -- The Australian ... universal healthcare coverage and good access to facilities ... and its associated disease burden, well-defined regulatory guidelines, ... of a new manufacturing policy will drive the ... a focus on generic substitution and price cuts ...
(Date:9/2/2014)... 2014  Based on its recent analysis of ... & Sullivan recognizes Novian Health, Inc. with the ... Technology Innovation Leadership. Novian Health has greatly improved ... with its proprietary technology, Novilase ® Laser ... and easy-to-control ultrasound-guided thermo ablation device that performs ...
Breaking Medicine Technology:HealthLink Europe opens North American medical warehouse operation 2Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 2Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 3Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 4Australia Medical Devices Market worth $10.4 billion by 2020 Says a New Report Available at MarketOptimizer.org 5Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 2Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 3Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 4Novian Health Wins Acclaim from Frost & Sullivan for Novilase Interstitial Laser Ablation Therapy for Early-Stage Malignant Breast Tumors 5
... 15 GeoVax Labs, Inc. (OTC,Bulletin Board: GOVX), an ... and provided an,operational update for the quarter ended September ... September 30, 2007 The Company recorded a net ... 2007, compared to $283,434 for the same period in ...
... BRISBANE, Calif., Nov. 15 BiPar,Sciences, Inc., a ... announced it has initiated a Phase 2 study ... triple-negative breast,cancer that do not express the estrogen, ... the Phase 2 trial in this indication-which,represents a ...
Cached Medicine Technology:GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 2GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 3GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 4GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 5GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 6GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 7GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 8GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 9GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update 10BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data 2BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data 3
(Date:9/2/2014)... with less intensive (and expensive) practice patterns appear to ... patients unnecessary and excessive medical care, according to a ... "Growing concern about the costs and harms of medical ... avoid the provision of unnecessary care," said lead author ... Dartmouth Institute for Health Policy & Clinical Practice. ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 Evolve ... within the primary and urgent care arena, is ... opening coincides with a health fair the clinic ... incorporating technology to assist patients in achieving high ... Medical Clinics’ pricing structure is a groundbreaking change ...
(Date:9/2/2014)... 2014 The first trial involving ... implant ( http://www.depuypinnacle-lawsuit.com/depuy-pinnacle-hip-implant/ ) will soon get underway, ... District Court, Northern District of Texas, Bernstein Liebhard ... Johnson and its DePuy Orthopaedics unit are facing ... caused recipients to suffer serious and debilitating complications. ...
(Date:9/2/2014)... 02, 2014 The exclusive ClinicCRM patient ... designed to help doctors manage foreign patient flow, enable ... conversion rates and clink revenue. Since its launch in ... in sales revenue and a 70 percent increase in ... their own healthcare practices. , With its ease of ...
(Date:9/2/2014)... California, San Diego School of Medicine have identified an ... The findings, reported in the current issue of PNAS, ... mortality worldwide. An estimated 40,000 women in America will ... American Cancer Society. , "The take-home message of the ... target breast cancer metastasis through a pathway regulated by ...
Breaking Medicine News(10 mins):Health News:Residency training predicts physicians' ability to practice conservatively 2Health News:Evolve Medical Clinics Announces Grand Opening of Annapolis, Maryland Location 2Health News:Evolve Medical Clinics Announces Grand Opening of Annapolis, Maryland Location 3Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 4Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 2Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 3Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 4Health News:Enzyme controlling metastasis of breast cancer identified 2
... But researcher stresses risk is still low , , MONDAY, Jan. ... the risk of developing brain cancer at a young age ... people with malignant brain tumors and 238 people with no ... most common type of brain cancer. Patients survive an average ...
... heart disease to rest , , MONDAY, Jan. 26 (HealthDay News) ... in vegetable oils, nuts and seeds possibly being bad for ... American Heart Association claims. , "There has been a lot ... might be bad," said William S. Harris, the nutritionist heading ...
... of American Physicians, Inc. Chief Executive Officer James L. ... Spirit of Life(R) Award, City of Hope,s ... celebrating Mr. Weidner and his award will be held ... Saturday, November 14. Spirit of Life(R) Award honorees ...
... Buy is Exclusive Retail Partner WARREN, N.J., Jan. ... VM ) announced today that it is joining ... of the LG Pink Flare limited edition handset, ... (Photo: http://www.newscom.com/cgi-bin/prnh/20090126/NY62794 ) , (Logo: ...
... Nephros, Inc. (Pink Sheets: NEPH), a medical device company ... control, and water purification, today announced that its common ... the symbol "NEPH." The Company also announced that ... the NYSE Alternext US LLC (formerly, the American Stock ...
... people tend to overestimate the dangers, study finds, , , ... the minds of U.S. minorities and the disabled more ... , Ethnic minorities, as well as the disabled and ... changes based on terrorism fears, such as avoiding certain ...
Cached Medicine News:Health News:Omega-6 Fatty Acids Can Be Good for You 2Health News:Omega-6 Fatty Acids Can Be Good for You 3Health News:James L. Weidner Named 2009 Spirit of Life(R) Award Recipient by City of Hope 2Health News:Virgin Mobile USA Launches Limited Edition Pink Flare Handset to Benefit Susan G. Komen for the Cure(R) 2Health News:Virgin Mobile USA Launches Limited Edition Pink Flare Handset to Benefit Susan G. Komen for the Cure(R) 3Health News:Nephros Common Stock Now Quoted in Pink Sheets 2Health News:Nephros Common Stock Now Quoted in Pink Sheets 3Health News:Terror Fears Tougher on Minorities, Disabled 2Health News:Terror Fears Tougher on Minorities, Disabled 3
... 400 System is an automated multiplexing platform ... SNP detection, pathogen sequence detection and pharmacogenetics ... be applied to an open and flexible ... be reused until all tests sites have ...
... venous pressure monitoring, blood sampling, and ... polyurethane PICC line sets offer:, , ... Micropuncture Introducer Needle, Biocompatible Polyurethane ... to patient specific anatomy. Remove catheter ...
Cable connections for 5 different adapters: Storz, ACMI, Pentax, Wolf and Olympus....
... epTIPS Filter have an integrated ... without "self-sealing" additives. This filter provides ... by aerosols, and it does not ... incorrect pipetting. Samples can then be ...
Medicine Products: